# A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

> **NCT05126719** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Miracogen Inc.** · enrollment: 238 (estimated)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** MRG003
- **DRUG:** Capecitabine tablets
- **DRUG:** Docetaxel injection

## Key facts

- **NCT ID:** NCT05126719
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-06
- **Primary completion:** 2024-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126719, "A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05126719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*